تداخلات ليفوميلناسيبران

Serotonin Syndrome Serotonin-norepinephrine reuptake inhibitors (SNRIs), including FETZIMA, can precipitate serotonin syndrome, a potentially life-threatening condition. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ) and Warnings and Precautions ( 5.2 )] . (نشرة ليفوميلناسيبران، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة البلادونا والأفيون، التداخلات الدوائية)

Intervention: Avoid concomitant use of FETZIMA and alcohol [see Clinical Pharmacology ( 12.3 )] . (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة أمفيتامين، التحذيرات والاحتياطات)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (نشرة أمفيتامين وديكستروأمفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (نشرة أوكسيكودون، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوكسيمورفون، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوليسيريدين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (نشرة إيدوكسابان، التداخلات الدوائية)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (نشرة ليفوميلناسيبران، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة باراسيتامول وكودايين، الاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (نشرة بروميثازين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بروميثازين وكودايين، التداخلات الدوائية)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بنتازوسين ونالوكسون، الاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين، التداخلات الدوائية)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، التداخلات الدوائية)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بوتورفانول، الاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (نشرة ليفوميلناسيبران، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (نشرة درونيدارون، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (نشرة ليفوميلناسيبران، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ريميفنتانيل، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة زيبراسيدون، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (نشرة ليفوميلناسيبران، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (نشرة فلومازينيل، تحذير مؤطر)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة فنتانيل، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome Serotonin-norepinephrine reuptake inhibitors (SNRIs), including FETZIMA, can precipitate serotonin syndrome, a potentially life-threatening condition. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (نشرة ليفوميلناسيبران، موانع الاستعمال)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (نشرة كاربامازيبين، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة كودايين، التداخلات الدوائية)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (نشرة لورازيبام، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ليسديكسامفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة ليفورفانول، الاحتياطات)

Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ) and Warnings and Precautions ( 5.2 )] . (نشرة ليفوميلناسيبران، موانع الاستعمال)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة مورفين، التداخلات الدوائية)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (نشرة ميتاكسالون، التداخلات الدوائية)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ميثادون، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ميثامفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (نشرة ليفوميلناسيبران، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

الجمع بين نبتة سانت جون ومضادات الاكتئاب والأدوية السيروتونينية الأخرى يزيد خطر متلازمة السيروتونين. (NCCIH, St. John's Wort)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون، التداخلات الدوائية)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وإيبوبروفين، الاحتياطات)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وباراسيتامول، الاحتياطات)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وكلورفينيرامين، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وهوماتروبين، التداخلات الدوائية)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدرومورفون، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (نشرة إبراتروبيوم وسالبوتامول، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (نشرة أدرينالين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة أرتيكايين وأدرينالين، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (نشرة أرفورموتيرول، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Inform patients about the increased risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions ( 7.1 )] . (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Inform patients about the increased risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions ( 7.1 )] . (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (نشرة إسزوبيكلون، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Inform patients about the increased risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions ( 7.1 )] . (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (نشرة أوكسيبات الصوديوم، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة أوميكليدينيوم وفيلانتيرول، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Examples: Ketoconazole, itraconazole, clarithromycin Alcohol Clinical Impact: Concomitant use of FETZIMA and alcohol may result in accelerated release of levomilnacipran. (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (نشرة إيزوبرينالين، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة بريلوكايين وأدرينالين، التداخلات الدوائية)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (نشرة بريمونيدين، التداخلات الدوائية)

Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…hydrochloride extended-release tablets (XL), concurrent administration of bupropion hydrochloride extended-release tablets (XL) and agents that lower the seizure threshold (e.g., other bupropion products, antipsychotics, antidepressants, theophylline, or systemic corticosteroids) should be undertaken only with extreme caution [see Warnings and Precautions (5.3)] . (نشرة بوبروبيون، التداخلات الدوائية)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (نشرة بوبيفاكايين وأدرينالين، التحذيرات والاحتياطات)

Inform patients about the increased risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions ( 7.1 )] . (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة بوديزونيد وفورموتيرول، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

DRUG INTERACTIONS Because pimozide prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with other drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval. (نشرة بيموزيد، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (نشرة توريميفين، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (نشرة تيربوتالين، الاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The CNS depressant effects of Zanaflex with alcohol and other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants) may be additive [see Drug Interactions ( 7.4 )] . (نشرة تيزانيدين، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (نشرة تيمازيبام، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (نشرة داريدوريكسانت، التحذيرات والاحتياطات)

Caution should be taken when darifenacin extended-release tablets is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants ( 7.2 ) (نشرة داريفيناسين، التداخلات الدوائية)

Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (نشرة دروبيريدول، التداخلات الدوائية)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (نشرة درونابينول، التحذيرات والاحتياطات)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (نشرة ديازيبام، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (نشرة ديسموبريسين، التداخلات الدوائية)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (نشرة ديسيكلومين، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (نشرة ريفابنتين، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (نشرة ريفامبيسين، التداخلات الدوائية)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (نشرة زاليبلون، التحذيرات)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (نشرة زولبيديم، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة سالبوتامول، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة سالميتيرول، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (نشرة سكوبولامين، التحذيرات والاحتياطات)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (نشرة سلفاميثوكسازول وتريميثوبريم، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…syndrome, uncorrected electrolyte imbalance, such as hypokalemia or hypomagnesemia and cardiac disease, such as heart failure, myocardial infarction, or bradycardia), and patients receiving Class IA antiarrhythmic agents (quinidine, procainamide), or Class III antiarrhythmic agents (amiodarone, sotalol), tricyclic antidepressants, macrolides, and antipsychotics. (نشرة سيبروفلوكساسين، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology ( 12.3 )] . (نشرة سيناكالسيت، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (نشرة غليكوبيرولات، التداخلات الدوائية)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (نشرة غيفيتينيب، التداخلات الدوائية)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (نشرة فازوبريسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (نشرة فورموتيرول، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (نشرة فوسفومايسين، التداخلات الدوائية)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (نشرة فوسفينيتوين، التداخلات الدوائية)

…prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic antidepressants, and certain macrolides and fluoroquinolones. (نشرة فوسكارنت، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (نشرة فيزوستيغمين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (نشرة فينيتوين، التداخلات الدوائية)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (نشرة فينيليفرين، التداخلات الدوائية)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التداخلات الدوائية)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (نشرة كاريزوبرودول، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Examples: Ketoconazole, itraconazole, clarithromycin Alcohol Clinical Impact: Concomitant use of FETZIMA and alcohol may result in accelerated release of levomilnacipran. (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (نشرة كلورازيبات، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة كلوروبروكايين، الاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (نشرة كلونازيبام، التداخلات الدوائية)

Tricyclic antidepressants Clinical Implication Concomitant use of tricyclic antidepressants with clonidine can increase blood pressure and may counteract the hypotensive effects of clonidine. (نشرة كلونيدين، التداخلات الدوائية)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (نشرة كوكايين، التداخلات الدوائية)

It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. (نشرة كويتيابين، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Examples: Ketoconazole, itraconazole, clarithromycin Alcohol Clinical Impact: Concomitant use of FETZIMA and alcohol may result in accelerated release of levomilnacipran. (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (نشرة لوراسيدون، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة ليدوكايين، التداخلات الدوائية)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (نشرة ليدوكايين وأدرينالين، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (نشرة ليفوثيروكسين، التداخلات الدوائية)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (نشرة ليفوسالبوتامول، التداخلات الدوائية)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (نشرة ليمبوريكسانت، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (نشرة ليوثيرونين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (نشرة موكسيفلوكساسين، التحذيرات والاحتياطات)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (نشرة ميبيفاكايين، التحذيرات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (نشرة ميثسكوبولامين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (نشرة ميفلوكين، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (نشرة نالبوفين، التداخلات الدوائية)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Plasma concentrations of CYP2D6 substrates (e,g. tricyclic antidepressants such as desipramine or imipramine) may increase when they are co-administered with haloperidol. (نشرة هالوبيريدول، التداخلات الدوائية)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

Examples: NSAIDs, aspirin, and warfarin Strong CYP3A4 Inhibitors Clinical Impact: Concomitant use of FETZIMA with strong CYP3A4 inhibitors increases levomilnacipran exposure [see Pharmacokinetics ( 12.3 )] . (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (نشرة ليفوميلناسيبران، التداخلات الدوائية)

Such drugs may include many antiarrhythmics, some phenothiazines, tricyclic antidepressants, and oral macrolides. (نشرة بروبافينون، التحذيرات والاحتياطات)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (نشرة بروبرانولول، التداخلات الدوائية)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (نشرة بريكسبيبرازول، التحذيرات والاحتياطات)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (نشرة بنزتروبين، التحذيرات)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (نشرة بيرفينازين، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (نشرة تياغابين، التحذيرات)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (نشرة تيربينافين، التداخلات الدوائية)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (نشرة حمض الفالبرويك، التداخلات الدوائية)

Such drugs include phenothiazines, cisapride, bepridil, tricyclic antidepressants, certain oral macrolides, and certain fluoroquinolones. (نشرة دوفيتيليد، التحذيرات)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (نشرة ديفالبروكس (فالبروات)، التداخلات الدوائية)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (نشرة كاربيدوبا، التداخلات الدوائية)

…placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (نشرة كاريبرازين، التحذيرات والاحتياطات)

Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide). (نشرة كلوزابين، التداخلات الدوائية)

Cytochrome P450 IID6 is an enzyme critical to the metabolism of many drugs, notably including mexiletine , some phenothiazines , and most polycyclic antidepressants . (نشرة كينيدين، التداخلات الدوائية)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (نشرة لوفاستاتين، التحذيرات)

Activation of mania/hypomania has also been reported in a small proportion of patients with mood disorders who were treated with other antidepressants. (نشرة ليفوميلناسيبران، التحذيرات والاحتياطات)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (نشرة هيدروكسيزين، الاحتياطات)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (نشرة إنتاكابون، الاحتياطات)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (نشرة روبينيرول، التداخلات الدوائية)